FDA Clears Silk Road’s Enroute Transcarotid Neuroprotection System
This article was originally published in The Gray Sheet
Executive Summary
The agency says it is the first such device designed to access the carotid arteries directly through an incision in the neck, instead of via a transfemoral catheter. Enroute reverses blood flow during carotid stenting or angioplasty to keep emboli away from the brain.
You may also be interested in...
Deals Of The Year: Cast Your Vote For Top Financing Of 2017
It's time for In Vivo's 10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.